Diaz Lopez Cristina*
Volume6-Issue6
Dates: Received: 2025-05-23 | Accepted: 2025-06-23 | Published: 2025-06-30
Pages: 815-828
Abstract
Resveratrol is a polyphenolic compound naturally found in various plants, notably in red grapes, and initially isolated from the roots of white hellebore. Due to its potential health-promoting properties, it has gained increasing attention in the fields of nutrition, cosmetics, and food technology. Its growing popularity as a dietary supplement has highlighted the need for a comprehensive safety assessment to ensure proper regulatory oversight.
This narrative review evaluates the safety of Trans-resveratrol as a food ingredient by addressing the four key stages of risk assessment: Hazard identification, hazard characterization, exposure assessment, and risk characterization. A literature search was conducted using PubMed and ScienceDirect, focusing on studies that examine bioavailability and toxicity in vitro, in animal models and in human clinical trials. Reports from food safety agencies such as AESAN and EFSA, as well as European regulatory documents, were also consulted.
Current scientific evidence suggests that Trans-resveratrol exerts beneficial effects-including antioxidant, anti-inflammatory, antiestrogenic, and antibacterial properties-with relatively low toxicity. However, its pharmacokinetics and bioavailability are significantly influenced by factors such as dose, gut microbiota, and food matrix, resulting in high interindividual variability. Regulatory authorities recommend a maximum supplemental dose of 150 mg/day. Although it is also present in food, dietary intake contributes minimally to overall exposure.
Despite promising results, concerns remain regarding its long-term safety. Adverse effects—primarily gastrointestinal—have been reported at high doses. Therefore, generalized high-dose consumption is not currently supported by sufficient evidence. Accurate labeling and adherence to regulatory limits are essential for consumer safety. Further research is needed to better understand Trans-resveratrol’s metabolism, safety, and therapeutic potential in humans, particularly in the context of long-term use.
FullText HTML
FullText PDF
DOI: 10.37871/jbres2134
Certificate of Publication

Copyright
© 2025 Cristina DL, Distributed under Creative Commons CC-BY 4.0
How to cite this article
Cristina DL. Trans - Resveratrol as a Food Ingredient Safety Assessment. J Biomed Res Environ Sci. 2025 Jun 30; 6(6): 815-828. doi: 10.37871/jbres2134, Article ID: JBRES2134, Available at: https://www.jelsciences.com/articles/ jbres2134.pdf
Subject area(s)
References
- Meng T, Xiao D, Muhammed A, Deng J, Chen L, He J. Anti-inflammatory action and mechanisms of resveratrol. Molecules. 2021 Jan 5;26(1):229. doi: 10.3390/molecules26010229. PMID: 33406713; PMCID: PMC7795473.
- Shaito A, Posadino AM, Younes N, Hasan H, Halabi S, Alhababi D, et al. Potential adverse effects of resveratrol: a literature review. Int J Mol Sci. 2020 Mar 18;21(6):2084. doi: 10.3390/ijms21062084. PMID: 32197410; PMCID: PMC7139367.
- Cione E, La Torre C, Cannataro R, Caroleo MC, Plastina P, Gallelli L. Quercetin, epigallocatechin gallate, curcumin, and resveratrol: from dietary sources to human microRNA modulation. Molecules. 2020 Jan 1;25(1):63. doi: 10.3390/molecules25010063. PMID: 31878082; PMCID: PMC6983040.
- Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018 Sep 9;6(3):91. doi: 10.3390/biomedicines6030091. PMID: 30205574; PMCID: PMC6164842.
- Tian B, Liu J. Resveratrol: a review of plant sources, synthesis, stability, modification and food application. J Sci Food Agric. 2020 Mar;100(4):1392–404. doi: 10.1002/jsfa.10152. PMID: 31756276.
- Riccio BVF, Spósito L, Carvalho GC, Ferrari PC, Chorilli M. Resveratrol isoforms and conjugates: a review from biosynthesis in plants to elimination from the human body. Arch Pharm (Weinheim). 2020 Dec;353(12):e2000146. doi: 10.1002/ardp.202000146. PMID: 32974977.
- Ratz-Łyko A, Arct J. Resveratrol as an active ingredient for cosmetic and dermatological applications: a review. J Cosmet Laser Ther. 2019 Apr;21(2):84–90. doi: 10.1080/14764172.2018.1469767. PMID: 29723052.
- Repossi G, Das UN, Eynard AR. Molecular basis of the beneficial actions of resveratrol. Arch Med Res. 2020 Feb;51(2):105–14. doi: 10.1016/j.arcmed.2020.03.002. PMID: 32204999.
- Zhang LX, Li CX, Kakar MU, Khan MS, Wu PF, Amir RM, et al. Resveratrol (RV): a pharmacological review and call for further research. Biomed Pharmacother. 2021 Mar;143:112164. doi: 10.1016/j.biopha.2021.112164. PMID: 33388241.
- Detampel P, Beck M, Krähenbühl S, Huwyler J. Drug interaction potential of resveratrol. Drug Metab Rev. 2012 Sep;44(3):253–65. doi: 10.3109/03602532.2012.712598. PMID: 22901046.
- Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168–75. doi: 10.1158/1940-6207.CAPR-10-0054. PMID: 20713696.
- Zha W. Transporter-mediated natural product-drug interactions for the treatment of cardiovascular diseases. J Food Drug Anal. 2018 Apr;26(2 Suppl):S32–44. doi: 10.1016/j.jfda.2018.01.001. PMID: 29703552; PMCID: PMC5937027.
- Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React. 1995;17(1):1–3. PMID: 7772694.
- Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 2007 May;139(3):475–85. doi: 10.1111/j.1365-2141.2007.06840.x. PMID: 17854384.
- Novelle MG, Wahl D, Diéguez C, Bernier M, de Cabo R. Resveratrol supplementation: where are we now and where should we go? Aging Res Rev. 2015 Mar;21:1–15. doi: 10.1016/j.arr.2014.10.004. PMID: 25445574; PMCID: PMC4303791.
- European Union. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Off J Eur Communities. 2002 Jul 12;L183:51–7.
- Ferry-Dumazet H, Garnier O, Matsuda MM, Vercauteren J, Belloc F, Billiard C, et al. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis. 2002 Aug;23(8):1327–33. doi: 10.1093/carcin/23.8.1327. PMID: 12151356.
- Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 2016;14(1):4368. doi: 10.2903/j.efsa.2016.4368.
- Informe del comité científico de la AESAN sobre la aplicación de luz UVC para la introducción de compuestos bioactivos en uvas. AESAN-2007-009. 2007;15–30.
- Commission Implementing regulation (EU) 2021/51 of 22 January 2021 authorizing a change of the conditions of use of the novel food 'trans-resveratrol' under Regulation (EU) 2015/2283. Off J Eur Communities. 2021 Jan 22;L23:10–12.
- Masís BA, Vega SM, Sánchez VJP. El resveratrol y sus posibles usos como nueva terapia farmacológica. Rev Med Costa Rica Centroam. 2013;70(608):679-84.
- Weiskirchen S, Weiskirchen R. Resveratrol: how much wine do you have to drink to stay healthy? Adv Nutr. 2016 Jul;7(4):706–18. doi: 10.3945/an.115.011627. PMID: 27422505; PMCID: PMC4942868.
- Edwards J, Stannard D, Burger D, Hofmann P. Resveratrol embryo-fetal study in the CD rat by dietary administration. DSM Nutr Products. 2007;25:210.
- Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004 Dec;82(2):614–9. doi: 10.1093/toxsci/kfh263. PMID: 15329443.
- Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, Booth TD, et al. Oncogenicity evaluation of resveratrol in p53(+/-) mice. Food Chem Toxicol. 2007 Jan;45(1):55–63. doi: 10.1016/j.fct.2006.07.015. PMID: 16965847; PMCID: PMC1855246.
- Navarro I, Periago MJ, García FJ. Estimación de la ingesta diaria de compuestos fenólicos en la población española. Rev Esp Nutr Hum Diet. 2017;21(4):320-6. doi: 10.14306/renhyd.21.4.357.
- Lachenmeier DW, Godelmann R, Witt B, Riedel K, Rehm J. Can resveratrol in wine protect against the carcinogenicity of ethanol? A probabilistic dose-response assessment. Int J Cancer. 2014 Jan 1;134(1):144–53. doi: 10.1002/ijc.28229. PMID: 23784940.
- Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for resveratrol? Is a new set of recommendations necessary? Ann N Y Acad Sci. 2013 Apr;1290(1):1–11. doi: 10.1111/nyas.12160. PMID: 23855460.
- Erlank H, Elmann A, Kohen R, Kanner J. Polyphenols activate Nrf2 in astrocytes via H2O2, semiquinones, and quinones. Free Radic Biol Med. 2011 Dec 15;51(12):2319–27. doi: 10.1016/j.freeradbiomed.2011.09.027. PMID: 21964393.
- Szende B, Tyihák E, Király-Véghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med. 2000 Jun 30;32(2):88–92. doi: 10.1038/emm.2000.13. PMID: 10901164; PMCID: PMC3055234.
- Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008 Aug;8(2):157–68. doi: 10.1016/j.cmet.2008.06.011. PMID: 18599363.
- Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996;59(1):PL15–21. doi: 10.1016/0024-3205(96)00260-3. PMID: 8684261.
- San Hipólito-Luengo Á, Alcaide A, Ramos-González M, Cercas E, Vallejo S, Romero A, et al. Dual effects of resveratrol on cell death and proliferation of colon cancer cells. Nutr Cancer. 2017;69(7):1019–27. doi: 10.1080/01635581.2017.1359324. PMID: 28937798.
- Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010 Nov 15;70(22):9003–11. doi: 10.1158/0008-5472.CAN-10-2364. PMID: 20935227; PMCID: PMC2982884.
- Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 2011 Sep;4(9):1419–25. doi: 10.1158/1940-6207.CAPR-11-0148. PMID: 21774592; PMCID: PMC3173869.
- La Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010 Jul;49(7):449–54. doi: 10.2165/11531820-000000000-00000. PMID: 20545556.
- Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial. Diabetes. 2013 Apr;62(4):1186–95. doi: 10.2337/db12-0975. PMID: 23349451; PMCID: PMC3609591.
- Almeida L, Vaz-da-Silva M, Falcão A, Soares E, Costa R, Loureiro AI, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009 May;53 Suppl 1:S7–15. doi: 10.1002/mnfr.200800177. PMID: 19194969.